These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28436256)

  • 41. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 42. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population.
    Muhlestein JB; Kammerer J; Bair TL; Knowlton KU; Le VT; Anderson JL; Lappé DL; May HT
    ESC Heart Fail; 2021 Feb; 8(1):691-696. PubMed ID: 33331114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.
    Stawowczyk E; Ward T; Paoletti E; Senni M; de Arellano AR
    Cost Eff Resour Alloc; 2024 May; 22(1):42. PubMed ID: 38769560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings.
    Neuenschwander JF; Silverstein AR; Teigland CL; Kumar S; Zeng EY; Agiro AT; Pottorf WJ; Peacock WF
    Adv Ther; 2023 Mar; 40(3):1204-1223. PubMed ID: 36652174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
    Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
    Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
    Murat S; Kaya H; Çavuşoğlu Y; Yılmaz MB
    Turk Kardiyol Dern Ars; 2021 Apr; 49(3):198-205. PubMed ID: 33847269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
    van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
    Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease.
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2019; 39(5):513-522. PubMed ID: 31027897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
    Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The burden of hyperkalemia in Germany - a real world evidence study assessing the treatment and costs of hyperkalemia.
    Haas JS; Krinke KS; Maas C; Hardt T; Barck I; Braun S
    BMC Nephrol; 2020 Aug; 21(1):332. PubMed ID: 32770956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacology of hyperkalemia].
    Rosano GMC
    G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e8-e12. PubMed ID: 34935774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
    Epstein M; Reaven NL; Funk SE; McGaughey KJ; Oestreicher N; Knispel J
    Am J Manag Care; 2015 Sep; 21(11 Suppl):S212-20. PubMed ID: 26619183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
    Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
    Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Model to Predict Risk of Hyperkalemia in Patients with Chronic Kidney Disease Using a Large Administrative Claims Database.
    Sharma A; Alvarez PJ; Woods SD; Dai D
    Clinicoecon Outcomes Res; 2020; 12():657-667. PubMed ID: 33204127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Hyperkalemia in Heart Failure.
    Altay H; Çavuşoğlu Y; Çelik A; Demir Ş; Kılıçarslan B; Nalbantgil S; Temizhan A; Tokgöz B; Ural D; Yeşilbursa D; Yıldırımtürk Ö; Yılmaz MB
    Turk Kardiyol Dern Ars; 2021 Oct; 49(Supp1):1-32. PubMed ID: 34738907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.